ContextMyocardial infarction (MI) and ischemic stroke are thought to be caused by matrix
digestion by metalloproteinases (MMPs) leading to rupture of atherosclerotic plaques …

BACKGROUND: A hallmark feature of atherosclerosis is inflammation mediated by
prostaglandins (PGs) catalyzed by the enzyme cyclooxygenase (COX). The present study …

BACKGROUND:: Cyclooxygenase (COX)-2, a key regulatory enzyme in prostanoid
synthesis, plays an important role in inflammatory processes. The− 765G> C COX-2 …

Aspirin prevents thrombotic events by inhibiting platelet cyclooxygenase-1 (COX-1), thus
reducing thromboxane A2 formation and platelet aggregation. The C50T polymorphism of …

Cyclooxygenase‐derived prostaglandins modulate cardiovascular disease risk. We
genotyped 2212 Atherosclerosis Risk in Communities study participants (1,023 incident …

Background A critical clinical application of the Human Genome Project is to identify
functional variation in genes related to disease or responses to xenobiotics. This study …

Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular
event, most notably stroke and myocardial infarction. However, despite the demonstrated …

Objective The biologically active epoxyeicosatrienoic acids have protective vascular effects.
CYP2J2, CYP2C8, and CYP2C9 are known to be a source of epoxyeicosatrienoic acids in …

Cyclooxygenases (COXs) are the primary targets of aspirin and other non‐steroidal anti‐
inflammatory drugs (NSAIDs), and thus enzymes of major interest to pharmacology …

Cyclooxygenases (COX)-1 and-2 are the key enzymes in the conversion of arachidonic acid
to prostaglandins. COX-2 appears to play an emerging role in inflammation and …